Assessing the effects of Clemastine Fumarate on myelin repair in MS patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of Clemastine Fumarate as a potential therapy for myelin repair in patients with multiple sclerosis (MS). It utilizes multi-parametric MRI assessments to measure changes in myelin integrity and function. The study includes patients diagnosed with relapsing-remitting MS and aims to determine if Clemastine can promote remyelination, addressing a significant unmet need in MS treatment. The trial is conducted at the University of California, San Francisco, leveraging prior findings that suggest Clemastine may enhance the differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent must be obtained prior to any assessment being performed.
* Patients diagnosed with relapsing remitting multiple sclerosis and a disease duration of \< 15 years
* Male or female patients aged 18-55 years (inclusive)
* Use of appropriate contraception during period of trial (women). Before entry women must be:

  * Post-menopausal for at least 1 year OR
  * Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, male partner vasectomy or otherwise incapable of pregnancy) OR
  * Practicing a highly effective method of birth control if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study OR
  * Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) OR
  * Practicing true abstinence (when this is in line with the preferred and usual lifestyle of the subject) Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not an acceptable method.

Exclusion Criteria:

* Radiologic identification of marked brain atrophy relative to patients age based on recent MRI and interpretation of expert neuroradiologist or PI
* New lesion in most recent MRI (within 3 months)
* Hypersensitivity to clemastine or other arylalkylamine antihistamines, or any of the excipients.
* Treatment with corticosteroids within 30 days prior to screening.
* Expanded Disability Status Scale (EDSS) ≥ 4.5
* History of significant cardiac conduction block.
* History of cancer.
* Suicidal ideation or behavior in 6 months prior to baseline.
* Pregnancy, breastfeeding or planning to become pregnant.
* Involved with other study protocols simultaneously without prior approval.
* Concomitant use of any other putative remyelinating therapy as determined by the investigator.
* Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination.
* Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide.
* Serum creatinine \> 1.5 mg/dL; aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase \> 2 times the upper limit of normal. (Reported within 72 hours)
* History of drug or alcohol abuse within the past year.
* Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid \[MMA\] and homocysteine) or untreated hypothyroidism.
* Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases that in the PI's judgment may affect the interpretation of study results or patient safety.
* History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study
* Inability to participate in MRI, including extreme claustrophobia.
* Any dental braces or permanent or undetachable metals in the jaw or face.

Where it's running

• Sandler Neurosciences Building, Neurological Clinical Research Unit
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Ari J Green, MD, MCR — University of California, San Francisco
• Study coordinator: Harkeerat Halait, BS
• Email: Harkeerat.Halait@ucsf.edu
• Phone: 415-745-1304

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational study of patients with Multiple Sclerosis in Switzerland

  This study is trying to find out more about the early signs of Multiple Sclerosis and how it changes over time by looking at health data from patients in Switzerland.

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT06526364

• Using the Cionic Neural Sleeve to improve mobility in people with multiple sclerosis

  This study is testing if wearing the Cionic Neural Sleeve can help people with multiple sclerosis walk better and improve their overall mobility.

  Recruiting Cionic, Inc. · Cleveland, Ohio · NCT05964829

• Investigating risk factors for disability progression in Multiple Sclerosis

  This study is trying to find out what factors might make disability get worse in people with Multiple Sclerosis by looking at their medical history and MRI scans.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT05204459

• QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases

  This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07526493

• Can QSM MRI help tell MS from age-related brain changes in older adults

  This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07444047

• Escalation versus induction therapy for relapsing MS starting after age 50

  This project will test whether starting with stronger, highly effective treatments or beginning with moderate drugs and escalating later changes the risk of inflammatory relapses for people whose relapsing MS began after age 50.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07313462

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.